Transgene S.A.: management transactions · France · AMF

About Transgene S.A.

Transgene S.A. is a French biotechnology company listed on Euronext Paris under ticker TNG and ISIN FR0005175080. Headquartered in Strasbourg since its creation, the company designs and develops innovative cancer immunotherapies, with a strong focus on viral-vector-based approaches and individualized therapeutic vaccines. Founded in December 1979, Transgene is part of France’s long tradition in genetic engineering and remains a research-stage biopharmaceutical company, still pre-commercial, whose value creation depends on clinical proof-of-concept, platform differentiation, and proprietary assets. The company’s business model is built around proprietary technology platforms and a portfolio of clinical-stage drug candidates. Its lead asset is TG4050, an individualized therapeutic vaccine derived from the myvac® platform. TG4050 is designed for each patient based on tumor mutations identified through sequencing, and it leverages AI-enabled neoantigen prediction technology through a strategic collaboration with NEC Bio. Transgene is also advancing BT-001, an armed oncolytic virus aimed at solid tumors, as well as additional programs from its Invir.IO® platform. This positions the company in highly specialized segments of immuno-oncology, where scientific differentiation, intellectual property, and clinical readouts are critical. From a market perspective, Transgene remains a small-cap biotech focused on clinical assets rather than commercial products. Its investment case is primarily driven by development milestones, clinical data, and strategic partnerships. Recent company communications highlight encouraging clinical results for TG4050 and BT-001, alongside extended financial visibility supported by its reference shareholder Institut Mérieux/TSGH and equity financing transactions. As of late 2025, the company stated that its cash resources and committed support gave it funding runway through the end of December 2026. Transgene is mainly rooted in France, with its headquarters and historic operations in Strasbourg, while maintaining collaborations with a broad international network of academic and industrial partners. Its recent disclosures show sustained clinical momentum, especially around TG4050, which is currently the main medium-term value driver. Overall, Transgene combines niche scientific expertise, a differentiated technology base, and the high-risk/high-reward profile typical of listed biotech companies.